Unilateral axillary lymphadenopathy following COVID-19 vaccination: A case report and imaging findings

• Main Authors: Jennifer Ledezma Dominguez, BS, Steven C. Eberhardt, MD, Jonathan W. Revels, DO
• Format: Article
• Language: English
• Published: Elsevier 2021-07-01
• Series: Radiology Case Reports
• Subjects: COVID-19; Lymphadenopathy; Computed tomography; Mammogram; Ultrasound
• Online Access: http://www.sciencedirect.com/science/article/pii/S1930043321002211

As more people receive coronavirus disease 2019 (COVID-19) vaccinations, the side effects of the vaccines will become more apparent. One reported side effect that has come to light is unilateral axillary lymphadenopathy ipsilateral to the vaccination site. In general, unilateral axillary lymphadenopathy has a broad differential including malignancy, infection, autoimmune disorder, and iatrogenic etiologies. We present a case of a previously healthy 38-year-old woman who received her first dose of Pfizer COVID-19 vaccination 3 days prior to presenting to the emergency department complaining of 2 weeks of abdominal pain and 20-pound unintentional weight loss. Unilateral axillary lymphadenopathy, ipsilateral to the vaccination site, was found on a contrast-enhanced computed tomography examination of the chest, abdomen, and pelvis. Subsequent diagnostic mammograms did not demonstrate evidence of malignancy; however, axillary ultrasound again revealed nonspecific lymphadenopathy. A short-term follow-up axillary ultrasound was recommended, rather than a lymph node biopsy, given the history of recent vaccination. At clinical follow-up, the patient's abdominal pain resolved and no further weight loss was noted. This case report discusses the key components and workup recommendation of unilateral axillary lymphadenopathy in the setting of COVID-19 vaccination.